Key result
The alphaC IFMA assay provided better discrimination of mucinous ovarian cancers than inhibin RIA (90% vs 71%), and combined with CA125, detected 90% of all ovarian cancers.
Why the study?
Does the combination of alphaC IFMA and CA125 improve the detection of ovarian cancers compared to inhibin RIA or either marker alone in postmenopausal women?
Population
319 women, comprising healthy postmenopausal women (n=165) and women with ovarian cancers (n=154)
Comparison
alphaC IFMA alone or in combination with CA125 vs inhibin RIA (radioimmunoassay)
Design
Case-control
Authors
Loading...
alphaC IFMA plus CA125 may enhance ovarian cancer detection; leaves open clinical adoption pending validation.
Case-Control (n=319)
Does the combination of alphaC IFMA and CA125 improve the detection of ovarian cancers compared to inhibin RIA or either marker alone in postmenopausal women?
Absolute Event Rate: 90% vs 71%
The combination of alphaC IFMA and CA125 provides an effective dual biomarker test for detecting the majority of ovarian cancers.
Robertson et al. (1999) conducted a case-control in Ovarian cancer (n=319). alphaC IFMA (inhibin immunofluorometric assay) vs. inhibin RIA was evaluated on Discrimination of mucinous ovarian cancers. The alphaC IFMA assay provided better discrimination of mucinous ovarian cancers than inhibin RIA (90% vs 71%), and combined with CA125, detected 90% of all ovarian cancers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: